Alternatives to Livea

A fast, fully async start with a needle-free sublingual tirzepatide option and — a genuine upgrade since our last check — flat pricing stated in writing. The catch is a state list it still won't publish.

Compounded semaglutide at $69 a month and tirzepatide at $119, one flat price that SnagRx says covers the medication, the supplies, the doctor review and shipping, with no membership fee and cancellation by email or phone. Both figures are advertised against struck-through list prices of $299 and $399 under a live countdown clock, and the promise to lock that rate for life is marketing rather than a published term. It ships from licensed US pharmacies it never names, and publishes no list of the states it serves.

$99/mo semaglutide, $183/mo tirzepatide, all 50 states, a named physician personally reviewing every intake, and a real 5-7 day timeline — on a broader peptide platform where GLP-1 pricing is genuinely invisible unless you know to pull the page's own data bundle.

Async-first compounded GLP-1 with a rarity for this list — free health coaching — at a flat one-price-all-doses rate. Fast and friendly up front; the strict, non-refundable fine print is the trade-off.

FDA warning letter #721472 (Feb. 2026), which names newself.com. A flat, dose-independent price for both molecules — $99.97/mo semaglutide, $144.49/mo tirzepatide, same price at every dose — nationwide, though it requires 3 months upfront.

Flat at every dose - $99 semaglutide, $134 tirzepatide, all fifty states - which makes the annual math trivial. The site never names its operating company.

Pepti publishes the lowest semaglutide price in this entire roster — $99 a month, flat at every titration dose, with the medication, physician review, shipping, refill management and unlimited messaging with your prescribing doctor all inside it. Tirzepatide is $199 on the same all-in, flat-at-every-dose basis. That number is low enough to deserve skepticism, so it is worth saying exactly where it comes from: Pepti states it on a dedicated cost page, repeats it in its FAQ ('we keep pricing flat and transparent at $99/mo all-in'), and prices the comparison against Hims, Henry Meds and Mochi on the same page. It names two prescribing physicians and says its medication is compounded by FDA-registered 503A or 503B pharmacies, though it never names which. The real limits are reach and format: it ships to 36 states rather than 50, it is cash-pay only and bills no insurance, and its needle-free oral GLP-1/GIP drops cost $349 — well above its own injection.

$99 semaglutide, $149 tirzepatide, flat at every dose, all 50 states. Renewal prices match advertised prices in the checkout data, so the no-price-rise claim holds. A plan month is four weeks; the '12-month' plan at $999 is 48 weeks. Same operator as Lean Meds, altRx and NextMeds — one company, four storefronts — and that operator holds FDA letter 728236, still open.

This record changed completely between checks, and mostly for the better. The founding-member framing that dominated it a week ago is gone: read live on 2026-08-26 KERNX simply says "Semaglutide starts at $129/month and Tirzepatide starts at $229/month. Pricing varies by prescribed dose. No membership fee. No required 3 month plan." What has not gone is the cost outside those figures, and KERNX is unusually straight about it — a provider consultation fee applies when treatment is approved, at $25 for a message-based review, $35 for a standard live visit or $60 for a complex live visit. Two more things this record previously had wrong. It does say where it operates: licensed providers in all 50 states, repeated in its banner and its FAQ. And it publishes a real timeline: a free five-minute assessment, provider review typically within 24 hours, pharmacy processing 1–2 business days and transit 2–3, so most first orders arrive within three to five business days of approval. It also says nothing is charged until a provider approves you.